乐观
$835.20
情景价格
$1,000.770
-11.409 (-1.14%)收盘时
McKesson Corporation is a diversified healthcare services company, which focuses on advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (U.S.). The Prescription Technology Solutions (RxTS) segment helps solve medication access, affordability and adherence challenges for patients by working across healthcare to connect patients, pharmacies, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, hospital reference labs, and home healthcare agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Canada and Norway. It also offers oncology and specialty solutions.
McKesson Corp is a good buy right now due to its current price of $1,000.77 being below the analyst price target of $1,000, indicating potential upside. The stock has shown a strong year-to-date change of +21.54% and a solid 20-day change of +15.48%, suggesting positive momentum. However, the main risk is the insider selling, which has increased by 144.45% over the last month, indicating potential concerns about management's confidence in the stock.
BofA
—
2026-10-01
BofA
2026-10-01
目标价
—
RBC Capital
$845
2026-08-19
RBC Capital
2026-08-19
目标价
$845
Barclays
$925
2026-08-19
Barclays
2026-08-19
目标价
$925
Wells Fargo
$933
2026-08-11
Wells Fargo
2026-08-11
目标价
$933
Evercore ISI
$860
2026-08-06
Evercore ISI
2026-08-06
目标价
$860
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

Investment Insights: Focus on McKesson and Medtronic

US Stocks Decline Due to Inflation Data

Option Care Health Shares Surge on Acquisition News

Tech Stocks Volatility and Investment Outlook

Market Recap: Strong Performances from CrowdStrike and GE Vernova
McKesson Corporation is a diversified healthcare services company, which focuses on advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (U.S.). The Prescription Technology Solutions (RxTS) segment helps solve medication access, affordability and adherence challenges for patients by working across healthcare to connect patients, pharmacies, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, hospital reference labs, and home healthcare agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Canada and Norway. It also offers oncology and specialty solutions. It operates in the Healthcare sector (WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRI industry).
McKesson Corp is a good buy right now due to its current price of $1,000.77 being below the analyst price target of $1,000, indicating potential upside. The stock has shown a strong year-to-date change of +21.54% and a solid 20-day change of +15.48%, suggesting positive momentum. However, the main risk is the insider selling, which has increased by 144.45% over the last month, indicating potential concerns about management's confidence in the stock.
14 analysts cover MCK: 4 rate it Buy, 9 Hold and 1 Sell. The average price target is 942.83.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。